CorMedix announces presentation at ASHP on catheter related infections

CorMedix announced the abstract publication and poster presentation at the American Society of Health-System Pharmacists, ASHP, conference in Las Vegas, Nevada, December 4 – 8. The abstract being presented highlights research that was conducted by integrating multiple clinical and claims databases that track a large cohort of kidney failure patients on hemodialysis with central venous catheters. The conclusions from this retrospective study further underscore the significant mortality risk and long-term complications associated with catheter-related bloodstream infections. The data show that of the 51,161 CVC-HD patients studied, approximately 33% of patients initiated on HD with a CVC experience a CRBSI. Other findings include: Patients with CRBSIs had five times higher 30-day mortality rates vs. non-CRBSIs patients, as well as higher mortality rates seen at 90 days, 180 days and 1 year. Patients with CRBSI also experienced higher rates of long-term complications including Stroke, Peripheral Vascular Disease, Myocardial Infarction, Heart Failure, and had generally longer and more complicated hospital courses. Of diagnosed CRBSIs, 33% and 47% were developed within 30- and 90- days post-CVC insertion, respectively. Joseph Todisco, Chief Executive Officer of CorMedix commented, "The data being presented represent a continuation of the work by the CorMedix team to highlight the magnitude and severity of CRBSIs as a serious and frequent problem faced by the hemodialysis patient community. CorMedix is working to address this unmet medical need and has demonstrated in a large Phase III clinical study that DefenCath can reduce the incidence of CRBSIs in patients undergoing hemodialysis via CVC by approximately 71% with a good safety profile. CorMedix remains steadfast in our efforts to obtain marketing authorization and bring DefenCath to patients in 2023."